RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
1.320
+0.005 (0.38%)
At close: Aug 20, 2026, 4:00 PM EDT
1.320
0.00 (0.00%)
After-hours: Aug 20, 2026, 4:10 PM EDT
RenovoRx Employees
RenovoRx had 17 employees as of December 31, 2025. The number of employees increased by 7 or 70.00% compared to the previous year.
Employees
17
Change (1Y)
7
Growth (1Y)
70.00%
Revenue / Employee
$116,235
Profits / Employee
-$722,647
Market Cap
59.57M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17 | 7 | 70.00% |
| Dec 31, 2024 | 10 | 2 | 25.00% |
| Mar 31, 2024 | 10 | 0 | - |
| Dec 31, 2023 | 8 | -1 | -11.11% |
| Sep 30, 2023 | 10 | 0 | - |
| Jun 30, 2023 | 10 | 0 | - |
| Mar 31, 2023 | 10 | 0 | - |
| Dec 31, 2022 | 9 | 3 | 50.00% |
| Sep 30, 2022 | 10 | 0 | - |
| Jun 30, 2022 | 10 | 2 | 25.00% |
| Mar 31, 2022 | 10 | 4 | 66.67% |
| Dec 31, 2021 | 6 | -3 | -33.33% |
| Sep 30, 2021 | 10 | 1 | 11.11% |
| Jun 30, 2021 | 8 | - | - |
| Mar 31, 2021 | 6 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Heron Therapeutics | 128 |
| Xilio Therapeutics | 76 |
| eXoZymes | 32 |
| Boundless Bio | 28 |
| INmune Bio | 21 |
| ImageneBio | 18 |
| Edesa Biotech | 17 |
| MiNK Therapeutics | 15 |
RNXT News
- 8 hours ago - RenovoRx receives notice of allowance for new RenovoCath U.S. patent - TheFly
- 8 hours ago - RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment - GlobeNewsWire
- 3 days ago - RenovoRx reports Q2 EPS (5c), consensus (8c) - TheFly
- 3 days ago - RenovoRx raises FY26 revenue view to $3.75M-$4.25M from $3M-$4M - TheFly
- 7 days ago - RenovoRx Transcript: Status update - Transcripts
- 8 days ago - RenovoRx Earnings Call Transcript: Q2 2026 - Transcripts
- 8 days ago - RenovoRx Earnings release: Q2 2026 - Filings
- 8 days ago - RenovoRx Quarterly report: Q2 2026 - Filings